Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2012
Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.
Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2014Trial
- From complexity to clarity: aging bone marrow niche in bone and blood regeneration and malignancy.Bone research · 2026Review
- Cell and tissue reprogramming: Unlocking a new era in medical drug discovery.Pharmacological reviews · 2025Review
- 'Nomadic' Hematopoietic Stem Cells Navigate the Embryonic Landscape.Stem cell reviews and reports · 2025Review
- Diversity in the bone marrow niche: Classic and novel strategies to uncover niche composition.British journal of haematology · 2022Review
- The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2022Review
- Targeting the Hematopoietic Stem Cell Niche in β-Thalassemia and Sickle Cell Disease.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Pre-Transplantation Serum Parathyroid Hormone Influences the Number of Mobilized CD34+ Hematopoietic Stem Cells in Autologous Hematopoietic Stem Cell Transplantation.Reports of biochemistry & molecular biology · 2021Article
- Article
- Impaired thymopoiesis predicts for a high risk of severe infections after reduced intensity conditioning without anti-thymocyte globulin in double umbilical cord blood transplantation.Bone marrow transplantation · 2018Article
- New agents in HSC mobilization.International journal of hematology · 2017Review
- IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults.PloS one · 2015Article
- The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation.Blood · 2014Review
- Modulating the stem cell niche for tissue regeneration.Nature biotechnology · 2014Review
- Targeting the molecular and cellular interactions of the bone marrow niche in immunologic disease.Current allergy and asthma reports · 2014Review
- CD34(+) expansion with Delta-1 and HOXB4 promotes rapid engraftment and transfusion independence in a Macaca nemestrina cord blood transplant model.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Transplantation of 1 or 2 umbilical cord blood products is a useful alternative stem cell source. However, the limited number of stem cells in each infusion results in slow engraftment. In mouse models, administration of parathyroid hormone (PTH) is an effective way to enhance the ability of limited numbers of hematopoietic stem cells to support hematopoiesis. In this study, patients received either a myeloablative or a reduced-intensity double umbilical cord blood transplantation, followed by PTH at 100 μg/day for 28 days. Thirteen patients (median age, 42 years) were enrolled. All patients engrafted; the median time to neutrophil and platelet engraftment of >20 × 10(9) cells/L was 30 days and 61 days, respectively. The incidence of grade II-IV acute GVHD was 38.5% at day 100. Four deaths occurred before day 100, prompting early study closure. No patient who received a myeloablative regimen relapsed. Overall survival at 6 months after transplantation was 62%, and disease-free survival at 2 years was 39%. At the dose and schedule studied, there was no evidence that PTH influenced blood count recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.